Segregation of caffeine reward and aversion in the rat nucleus accumbens shell versus core.

The European Journal of Neuroscience
Mandy YeeDerek van der Kooy

Abstract

Caffeine, the most commonly consumed psychoactive drug in the world, is readily available in dietary sources, including soft drinks, chocolate, tea and coffee. However, little is known about the neural substrates that underlie caffeine's rewarding and aversive properties and what ultimately leads us to seek or avoid caffeine consumption. Using male Wistar rats in a place conditioning procedure, we show that systemic caffeine at a low intraperitoneal dose of 2 mg/kg (or 100 µM injected directly into the rostral, but not caudal, portion of the ventral tegmental area) produced conditioned place preferences. By contrast, high doses of systemic caffeine at 10 and 30 mg/kg produced conditioned place aversions. These aversions were not recapitulated by a caffeine analog restricted to the periphery. Both caffeine reward and aversion were blocked by systemic D1-like receptor antagonism using SCH23390, while systemic D2-like receptor antagonism with eticlopride had smaller effects on caffeine motivation. Most important, we demonstrated that pharmacological blockade of dopamine receptors using α-flupenthixol injected into the nucleus accumbens shell, but not core, blocked caffeine-conditioned place preferences. Conversely, α-flupenthixol ...Continue Reading

References

Dec 15, 1990·The Journal of Comparative Neurology·D S Zahm, L Heimer
Mar 1, 1991·Pharmacology, Biochemistry, and Behavior·N T BrockwellR J Beninger
Jun 1, 1989·The Journal of Pharmacy and Pharmacology·A WormaldM G Collis
Feb 1, 1988·Pharmacology, Biochemistry, and Behavior·R R Griffiths, P P Woodson
Jul 8, 1982·Brain Research·R F MuchaP Bucenieks
Jan 1, 1994·Pharmacology, Biochemistry, and Behavior·B E Garrett, S G Holtzman
Dec 19, 1995·Proceedings of the National Academy of Sciences of the United States of America·F E PontieriG Di Chiara
Oct 13, 1998·Pharmacology, Biochemistry, and Behavior·J B BedingfieldF A Holloway
Feb 3, 1999·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·N A Patkina, E E Zvartau
Jul 23, 1999·Annals of the New York Academy of Sciences·D S Zahm
Oct 31, 2002·Psychopharmacology·Carolyn F Brice, Andrew P Smith
Nov 26, 2002·Behavioural Brain Research·Gaetano Di Chiara
Apr 6, 2004·Proceedings of the National Academy of Sciences of the United States of America·Joseph A KimHoward L Fields
Mar 3, 2005·Pharmacology, Biochemistry, and Behavior·Gregory R Simpson, Anthony L Riley
Jun 1, 2005·Behavioural Brain Research·Rafal RygulaUrsula Havemann-Reinecke
Jun 10, 2005·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Valerie G OlsonEric J Nestler
Sep 1, 2005·European Journal of Pharmacology·Malika El YacoubiJean-Marie Vaugeois
Oct 28, 2005·Nature Neuroscience·Eric J Nestler
Jan 24, 2007·The European Journal of Neuroscience·Tsuyoshi YamaguchiMarisela Morales
Aug 5, 2008·Neuropharmacology·William A Carlezon, Mark J Thomas
Aug 8, 2008·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Steven R LavioletteHuibing Tan
Aug 16, 2008·The European Journal of Neuroscience·Laurie H L SellingsPaul B S Clarke
Mar 31, 2009·Human Psychopharmacology·Andrew Smith
Jul 29, 2009·Pharmacology, Biochemistry, and Behavior·Cristie Grazziotin NoschangCarla Dalmaz
Oct 6, 2009·Brain Research·Roy A Wise, Marisela Morales
Dec 25, 2009·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·Taryn E GriederDerek van der Kooy

❮ Previous
Next ❯

Related Concepts

Related Feeds

Basal Ganglia

Basal Ganglia are a group of subcortical nuclei in the brain associated with control of voluntary motor movements, procedural and habit learning, emotion, and cognition. Here is the latest research.